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Abstract  
Background: Each year approximately 450,000 new cases of invasive cervical carcinoma are diagnosed 
worldwide. The cervical cancer incidence rate is highest in countries that have little or no cytologic cervical 
cancer screening. There are many barriers to establishing cervical cancer screening programs in resource-poor 
settings. The main objective was to determine the cost of setting up and sustaining secondary cervical cancer 
prevention services in Uganda. Methods: In order to evaluate the use of alternative screening methods in a 
resource-poor setting, we instituted a study at the colposcopy and cervical pathology clinic at Mbarara Regional 
Referral Hospital in Uganda. Previously unscreened women ages 25years and above were screened using a 
combination of conventional cytology and direct visual inspection (DVI). The outcomes included costs of clinic 
set up, training costs, cost of equipments, salaries and supplies. Screening strategies were distinguished by the 
number of clinical visits, the use of 1 or 2 screening tests and screening frequency. Screening tests included DVI 
and cytology. Results: The screening started in April 2009 through aid of an American non government 
organization known as Program for Appropriate Technology in Health (PATH) which provided the initial 
funding for equipment and clinic set-up. Out of 4659 women screened in 2013, 73.2% were below 50 years, 
17.7% were 50 years and above. Majority of women (55.0%) come from Mbarara district, 71.3% were from 
rural areas outside Mbarara Municipality. The prevalence of HIV was 19.0%. Cervical intraepithelial neoplasia 
comprised (4.8%), 225cases, while cervical cancer comprised (2.7%) 125cases, 94.2% were treated with 
Cryotherapy, 5.3% were treated by LEEP and one total abdominal hysterectomy. The cost of reusable 
requirements for setting up a cervical cancer screening clinic was Ugshs 11,730,000.00. The cost of screening a 
population of 4659 in 2013 was 54, 302, 200.00, the cost of screening one woman using acetic acid was Ugshs 
152.00, and Pap smear per woman is Ugshs 55,000.00, while the cost of screening one woman using lugol’s 
iodine was Ugsh 4,000.00(the cost of reusable speculums, gloves,cotton and gauze is not included on individual 
patients).  The cost of cin treatment of a population of 3569 women was Ugshs 9,800,000.00 plus 2280.00USD. 
Cryotherapy per woman was Ugshs 46,226.00.(the cost of  gloves, cotton, guaze and reusable equipment such as 
speculums is not included). When using two  stationary clinic nurses the cost in salaries and training will be 
Ugshs 23,204,000.00, however if using outreach model the cost in allowances and training will be 85,450,000.00. 
When using a group of 20 volunteers for the outreach model the cost in allowances and training will be Ugshs 
33,050,000.00.(USD = Ugshs 4000.00). (The cost of gloves, cotton swabs and gauze is not included). 
Conclusion: Cytologic screening is several times more costly than direct visual inspection (DVI). Visual 
inspection screening of the cervical and treatment with Cryotherapy can be used as a cost effective alternative 
method to cytologic examination for control of cervical cancer in low resource areas. Using existing staff and 
integration of screening services into existing services into annual hospital budget helps in sustainability of 
donor initiated cervical cancer screening programs. Recommendations: Cervical cancer screening programs in 
low resource areas should adopt direct visual inspection using 3-5% acetic acid as the main screening method 
and “see and treat” approach for treatment of positive lesions. For program sustainability cervical cancer 
screening services should be integrated into the main hospital programs and annual budget. Existing personnel 
and infrastructure should be used for cost effectiveness and sustainability. 
Keywords: Resources, Initiation, Sustainability, Cervical Cancer, Prevention   
 
INTRODUCTION  
Each year approximately 450,000 new cases of invasive cervical carcinoma are diagnosed worldwide. The 
cervical cancer incidence rate is highest in countries that have little or no cytologic cervical cancer screening. 
There are many barriers to establishing cervical cancer screening programs in resource-poor settings. These 
include the demands of competing health needs, such as communicable disease; poorly developed health care 
services that tend to be focused on curative rather than preventive care; war and civil strife; and the fact that 
women in poor countries often are uninformed as to their needs for preventive health care. The traditional 
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method of screening, cervical cytology, presents an additional barrier. Cytologic-based screening programs 
require a relatively sophisticated infrastructure, including highly trained personnel, adequately equipped 
laboratories, and referral systems to communicate results of the test (which usually is delayed) to women. 
Because of the problems intrinsic to cytologic screening, considerable attention is being given to developing 
alternative methods, such as direct visual inspection (DVI) and human papillomavirus (HPV) DNA testing, for 
cervical cancer screening in resource-poor settings(Denny et al., 2000).  
The objective of cervical cancer screening is to reduce cervical cancer incidence and mortality by 
detecting and treating precancerous lesions. Conventional cytology is the most widely used cervical cancer 
screening test. Although cytology has been effective in reducing the incidence of and mortality from cervical 
cancer in developed countries in both opportunistic and—more dramatically—organized national programs, it 
has been less successful and largely ineffective in reducing disease burden in low-resource settings where it has 
been implemented. Liquid-based cytology, testing for infection with oncogenic types of human papillomaviruses, 
visual inspection with 3–5% acetic acid, magnified visual inspection with acetic acid, and visual inspection with 
Lugol's iodine have been evaluated as alternative tests(Sankaranarayanan et al., 2005). 
Cervical cancer is a leading cause of cancer-related death among women in developing countries, with 
up to 80% of patients presenting with advanced disease.  In resource-poor areas, such as sub-Saharan Africa, the 
growing number of women infected with human immunodeficiency virus (HIV) may further compound this 
problem because they have an increased risk of human papillomavirus (HPV) infection, the causal agent of 
cervical cancer. Cytology-based screening programs have decreased the incidence of invasive cervical cancer in 
many developed countries. However, cytologic screening requires an established laboratory, highly-trained 
cytotechnologists, and up to 3 visits for screening, evaluation of cytologic abnormal results, and treatment. In 
low-resource settings, such a strategy has proven difficult to implement and sustain. Recently, it has been 
suggested that less complex strategies may offer additional options. Such strategies replace the Papanicolaou 
smear with simple visual screening methods, such as direct visual inspection (DVI) in which the cervix is viewed 
after the application of an acetic acid solution, or HPV DNA testing. They also eliminate colposcopy, allowing 
for screening and treatment to be performed during the same visit. These screening approaches have shown 
promise in large trials conducted in low-resource settings; however, determining whether they will be clinically 
or cost-effective requires formal evaluation using analytic modeling methods(Goldie et al., 2001) 
Cervical cancer is a serious health problem, with nearly 500 000 women developing the disease each 
year worldwide. Most cases occur in less developed countries where no effective screening systems are available. 
Risk factors include exposure to human papillomavirus, smoking, and immune-system dysfunction. Most women 
with early-stage tumours can be cured, although long-term morbidity from treatment is common.(Waggoner, 
2003). Cervical cancer is highly preventable through cytologic screening programs that facilitate the detection 
and treatment of precancerous lesions. Such screening, however, requires an established laboratory, highly 
trained cytotechnologists, and up to three visits for screening, evaluation of cytologic abnormalities, and 
treatment and is therefore difficult to implement and sustain in settings with limited resources. Alternative 
methods, such as DNA testing for human papillomavirus (HPV) and simple visual screening, may prove more 
practical when incorporated into new strategies that are less dependent on existing laboratory infrastructure and 
require fewer visits. Consequently, timely implementation of a cost-effective screening strategy for use in 
developing countries is particularly critical (Goldie et al., 2005). 
There are different cervical cancer screening tests ranging from Human Papilloma Virus (HPV) 
detection, Papanicolou(Pap) smears, Liquid Based Cytology(LBC), Visual Inspection with 3-5% acetic acid(VIA) 
and Visual Inspection with Lugol’s iodne(VILI) also known as Schiller’s test. All these tests have different 
sensitivities, specificities and costs. The methods of treatment of precancerous lesions range from Cryotherapy, 
LEEP or Cervical Cone Biopsy. Diagnostic methods such as colposcopy and biopsy all differ. The choices of 
methods used differ in different programs and ministries depending on available resources. These programs 
range from “see and treat” methods to Colposcopy, biopsy and treatment. Different programs choose the most 
cost effective and sustainable methods depending on resources available. 
The total and individual annual expenditures on cervical cancer prevention and control in Uganda are 
not known. The colposcopy and cervical pathology (CCP) clinic at Mbarara Regional Referral Hospital (MRRH) 
handles all the clients and patients involved in cervical cancer prevention and care at MRRH. However there is 
no guidance for estimating the costs involved in cervical cancer prevention in low resource settings. The main 
objective was to determine the cost of setting up and sustaining secondary cervical cancer prevention services for 
a population of 5000 women (Sub County) for a period of one year, Uganda 
 
METHODS AND MATERIALS  
Study design: 
The design of the study was a retrospective study using secondary date from the colposcopy and cervical 
pathology (CCP) clinic at Mbarara Regional Referral Hospital. 
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Study site: 
The study was conducted in the CCP at Mbarara Regional Referral Hospital (MRRH). The hospital is located in 
Mbarara municipality which is 226 km (165 miles) south of Kampala, the capital city of Uganda. Mbarara 
Regional Referral Hospital is a 300 bed public hospital that serves as the referral hospital for ten districts in 
southwestern Uganda, with a population of about 4million people (Atukunda et al 2014). It is a teaching hospital 
for Mbarara University of Science and Technology, Faculty of Medicine and visiting students from other 
institutions. The hospital has obstetrics and gynecology department, with a maternity wing that conducts 
approximately 10,000 deliveries per year. The department is linked to four major operating theatres, a blood 
transfusion laboratory and is capable of providing comprehensive obstetric care. The department has a 
colposcopy clinic which runs on a daily basis from Monday to Friday starting at 0800houra to 1700 hours. The 
facility has a number of specialists who offer specialized services. This facility was thus suited to carry out this 
research. The data was collected between 1ST January and 31ST December 2013.   
Study population:  
All women who attended the colposcopy and cervical pathology clinic in the years 2013 were formed the study 
population. 
Inclusion criteria: 
All sexually active women who were in reproductive age and above were included in the study.  
Exclusion criteria: 
Women in reproductive age and above who were not sexually exposed were excluded from the study.  
Outcome variables: 
Cost of clinic set up, cost of training, cost of equipment of screening, cost of equipment for cervical pre-cancer 
treatment, cost of biopsies 
Independent variables: 
The independent variables included social demographic, obstetric and medical characteristics of clinic attendees. 
Sample size estimation: 
The sample size was 4659 that were screened in 2013. 
Sampling method: 
The method of sampling was by consecutive sampling. 
Statistical data analysis: 
The data was entered in an EXCEL spreadsheet and analyzed using SPSS statistical software, version 20 (SPSS, 
Chicago, IL, USA). Cross tabulations were conducted to obtain descriptive statistics which were presented as 
frequencies, percentages. 
Ethical considerations: 
Approval was sought from the department of Obstetrics and Gynecology Mbarara University of science and 
technology, Mbarara Regional Referral Hospital, Faculty of Medicine Research Committee and Mbarara 
University Institutional Research Board (IRB). 
Study procedures 
To evaluate the use of alternative screening methods in a resource-poor setting, we instituted a study at the 
colposcopy and cervical pathology clinic at Mbarara Regional Referral Hospital in Uganda. Previously 
unscreened women ages 25years and above were screened using a combination of conventional cytology and 
direct visual inspection (DVI).  In this article we present comparisons of the costs of clinic set up, training costs, 
cost of equipments, salaries, screening costs, cervical intraepithelial neoplasia (cin) treatment costs and cost of 
supplies. We adopted a societal perspective (i.e., all costs and benefits are included regardless to whom they 
accrue). During the five year period (2009-2013) every patient who underwent cervical cancer screening and 
treatment at MRRH was recorded and observed. These clients were then followed for a period of one year. The 
screening methods were recorded, as were the outcomes of all patients. Secondary clinic data was used to 
estimate the costs. The expenditures for each client were estimated from the records depending on the screening 
methods, treatment methods, diagnostic methods and supplies involved. The costs of screening by Pap smear, 
5% acetic acid, and Lugol’s iodine were directly determined. The cost of treatment by Cryotherapy was directly 
calculated from the cost of the Cryotherapy gun, the cost of nitrous oxide gas, transportation costs and others. 
The cost of LEEP and Hysterectomy was not calculated in this study.  Reusable instruments that were used in 
clinic set were not considered for total or individual annual costs. The cost of screening a population of 4659 at 
Mbarara Regional Referral Hospital in 2013 was determined.  From the results of 2013 estimates were made to 
determine the costs for screening a population of 5000women which is equivalent to a sub county in Uganda.  
We chose a population of 5000 because if we assume a clinic run by 2 nurses working for 20 days in a month 
and each nurse screening between 10 and 11 women per day this will translate into 4800-5820 women per year 
which is approximately 5000.  We chose the year 2013 because this is when we screened 4659 women which 
were closest to our target of 5000 women per year.  
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RESULTS  
We established that the screening started in April 2009 through aid of an American non government organization 
known as Program for Appropriate Technology in Health (PATH) which provided the initial funding for 
equipment and clinic set-up. The ministry of health of Uganda provided clinic space, personnel and consumables. 
For the Human resource, existing staff that were already on the government pay roll were recruited, except for 
the first 2 years whereby an extra nurse was hired by the donor. The nurses were supported by one gynecologist 
who was already employed by the neighboring Mbarara University of Science and Technology (MUST). 
Mobilization of women was through radios, television, churches and mosques, politicians and village health 
teams. 
 Out of 4659 women screened in 2013, 73.2% were below 50 years, 17.7% were 50 years and above, 
table: 1. The women came from the districts of southwestern Uganda and beyond, with majority (55.0%) coming 
from Mbarara district, table:2. Most of the women (71.3%) were from rural areas outside Mbarara Municipality. 
The prevalence of HIV was 19.0%. , table: 3. Cervical intraepithelial neoplasia(cin) comprised (4.8%), 225cases, 
while cervical cancer comprised (2.7%) 125cases, 94.22% were treated with Cryotherapy, 5.3% were treated by 
LEEP and one total abdominal hysterectomy, table: 4. The cost of reusable requirements for setting up a cervical 
cancer screening clinic was determined to be Ugshs 11,730,000.00, Table 5. The cost of screening a population 
of 4659 at Mbarara Regional Referral Hospital in 2013 was 54, 302, 200.00, the cost of screening one woman 
using acetic acid was Ugshs 152.00, and Pap smear per woman is Ugshs 55,000.00, while the cost of screening 
one woman using lugol’s iodine will be Ugsh 4,000.00, Table: 6. The cost of cin treatment of a population of 
3569 women is Ugshs 9,800,000.00 plus 2280.00USD. Cryotherapy per woman is Ugshs 46,226.00,( the cost of 
gloves ,cotton, gauze and reusable equipment such as speculums is not included on individual patients), table: 7. 
when using two stationary clinic nurses the cost in salaries and training will be Ugshs 23,204,000.00, however if 
using outreach model the cost in allowances and training will be 85,450,000.00, table 10. When using a group of 
20 volunteers for the outreach model the cost will be Ugshs 33,050,000.00 in allowances and training, table: 11. 
The cost of gloves, cotton swabs and guaze is not included. (USD =Ugshs 4000.00) 
Table: 1, Age distribution  
Age group Frequency (%) 
20-25 560(12.0) 
26-30 743(16.0) 
31-35 582(12.5) 
36-40 722(15.5) 
41-45 453(9.7) 
46-50 425(9.1) 
51-55 223(4.8) 
56-60 197(4.2) 
>60 253(5.4) 
Missing 416(8.9) 
<50 
50+ 
3403(73.2) 
824(17.7) 
25-49 
Out of(25-29) 
2953(63.5) 
1277(27.5) 
  
Out of 4659 women screened in 2013, 73.2% were below 50 years and therefore eligible for VIA, 
17.7% were 50 years and above and hence required Pap smear screening .Table:1 
Table 2, Geographical distribution 
District Frequency (%) 
Bushenyi 520(11.2) 
Foreign 9(0.2) 
Ibanda 57(1.2) 
Isingiro 711(15.3) 
Kamwenge 36(0.8) 
Kiruhura 223(4.8) 
Mbarara 2564(55.0) 
Ntungamo 177(3.8) 
Other 158(3.4) 
Rukungiri 62(1.3) 
Missing 132(2.8) 
The women came from the districts of southwestern Uganda and beyond, with majority (55.0) coming 
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from Mbarara district.Table:2 
Table 3, Social demographic and medical characteristics 
Variable Frequency (%) 
Pregnancy history 
Yes 
No 
Missing 
 
3554(76.4) 
205(4.4) 
886(19.1) 
HIV 
Negative  
Positive  
Missing 
 
3241(69.7) 
882(19.0) 
525(11.3) 
Residence 
Rural 
Urban 
Missing 
 
3316(71.3) 
1249(26.9) 
418(9.0) 
Phone availability 
Available 
None 
Missing 
 
1628(35.0) 
2963(63.7) 
53(1.1) 
Most of the women (71.3) were from rural areas outside Mbarara Municipality. The prevalence of HIV 
was 19.0%. Table:3 
Table: 4, Diagnosis and treatment methods 
Variable Frequency (%) 
Diagnosis  
Cervical cancer 
Pre-cancer 
Normal 
Missing  
 
125(2.7) 
225(4.8) 
4300(92.5) 
1(0.0) 
Pre-cancer treatment 
No 
Yes 
Total  
 
0(0.0) 
225(100.0) 
225 
Method of treatment  
Cryotherapy 
LEEP 
TAH 
 
212(94.22) 
12(5.33) 
1(0.0) 
Cervical intraepithelial neoplasia comprised (4.8%), 225cases, while cervical cancer comprised (2.7%) 
125cases, 94.22% were treated with Cryotherapy, 5.3% were treated by LEEP and one total abdominal 
hysterectomy. Table: 4 
Table 5: Cost involved in Clinic set up 
Item  Freq. Unit  Unit cost Units  Total  
Lithotomic bed 1 1 300.000 2 600.000. 
Autoclave  1 1 8,000,000 1 8,000,000. 
Sterilizing drums 1 1 300,000. 2 600,000. 
Kidney dishes  1 1 50,000. 5 250,000. 
Galipots  1 1 20,000. 10 200,000. 
Linen  1 Meter  5000. 100 500,000. 
Sponge holding 
forceps  
1 1 10,000. 100 1,000,000. 
Table  1 1 100,000. 2 200,000. 
Chairs 1 1 100,000 2 200,000. 
Buckets  2 1 30,000. 3 180,000. 
Total      11,730,000. 
The cost of reusable requirements for setting up a cervical cancer screening clinic was determined to be 
Ugshs 11,730,000.00, Table 5.( USD = Ugshs 4000.00) 
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Table 6: Cost of screening, diagnosis of 4659women in 2013 
Item  Freq. Unit Unit cost Units Total 
Acetic acid 5% 1 1ml/woman(20mls) 100. 3822 382,200.00 
Distilled water  1 Jelly can 50,000 4 200,000.00 
Pap smears kit 1 Kit 5000 824 4,120,000.00 
Reading pap  
smear 
1 1 50,000 824 41,200,000.00 
Total      45,902,200.00 
Colposcopy 
Lugol’s iodne  1 20ml/woman 200 225 900,000.00. 
Monsel’s paste  - - - - - 
Biopsy reading 
icc 
1 1 60,000. 125 7,500,000.00 
Total      54,302,200.00 
The cost of screening a population of 4659 at Mbarara Regional Referral Hospital in 2013 was 54, 302, 
200.00, the cost of screening one woman using acetic acid was Ugshs 152.00, and Pap smear per woman is 
Ugshs 55,000.00 which is 361 times higher than acetic acid screening. While the cost of screening one woman 
using lugol’s iodine will be Ugsh 4,000.00, Table: 6, 500mls of acetic acid cost Ugshs 50,000.00, 500mls of 
Lugols iodine cost Ugshs 100.000.00, (USD = Ugshs 4000.00). The cost of gloves, gauze and cotton has been 
excluded. 
Table 7: Cost of treatment of 4659 women 
Item  Freq. Unit Unit cost Units Total 
Cost of CIN Treatment One Cryotherapy unit, LEEP and Nitrous Oxide gas 
019000 MedGyn Cryotherapy 
system MGC-200 
1 1 1,300.00USD 1 1,300.00USD 
019010 British adaptor  for CO2 1 1 90.00USD 1 90.00USD 
019002/1905 MedGynTipGT-
1905 Exocervical convex ,19mm 
1 1 185.00USD 1 185.00USD 
019002/1910 MedGyn 
croyotherapy Tip GT1910 
Endo/Exocervical cervical small 
1 1 185.00USD 1 185.00USD 
Carrying case for Cryotherapy 
system 
1 1 55.00USD 1 55.00USD 
Cryopart Exhaust Filter 100-
1419 
1 1 15.00 1 15.00USD 
Shipping costs 1 1 450.00USD 1 450USD 
Total   2280.000USD 
Nitrous oxide cylinder deposit 1 Cylinder 500,000.00 6 3,000,000.00Ugs 
Gas price 1 Cylinder 800.000 212=Each cylinder 
40pple= 
5.3cylinders=6 
4,800,000.00Ugs 
Transport costs 1 1 2,000,000.00 1 2,000,000.00 
Total      9,800,490.00 
LEEP machine 1 1 7,000,000.00 1 7,118,209 
The cost of cin treatment of a population of 3569 women is Ugshs 9,800,000.00 plus 2280.00USD. 
Cryotherapy per woman is Ugshs 46,226.00, Table:7.(USD= Ugshs 4,000.00) 
Table 8: Cost of screening and diagnosis (5000people) 
Item  Freq. Unit Unit cost Units Total 
Acetic acid 5% 1 1ml/woman(20mls) 100. (73.2/100x5000) =3660 366,000.00 
Distilled water  1 Jelly can 50,000 5 250,000 
Pap smears kit 1 Kit 5000 (17.7/100x5000) =885 4,425,000.00 
Reading pap  smear 1 1 50,000 885 44,250,000.00 
Colposcopy 
Lugol’s iodne  1 20ml/woman 200 240 960,000.00 
Monsel’s paste  - - - - - 
Biopsy reading , icc 1 1 60,000. (2.7/100x5000) =135 8,100,000.00 
Total      58,351,000.00 
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The total cost of screening a population of 5000 will be 58, 255,000.00.  . The cost of acetic acid 
screening per woman is Ugshs 100.00 and Ugshs 55,000.00 (550 times higher) with Pap smear, but Ugshs 
4,000.00 with lugol’s iodine. Table:8.(USD =Ugshs 4000.00). 
Table: 9 Cost of treatment of CIN in population of 5000 women 
Item  Freq. Unit Unit cost Units Total 
Cost of CIN Treatment One Cryotherapy unit, LEEP and Nitrous Oxide gas 
019000 MedGyn 
Cryotherapy system 
MGC-200 
1 1 1,300.00USD 1 1,300.00USD 
019010 British 
adaptor  for CO2 
1 1 90.00USD 1 90.00USD 
019002/1905 
MedGynTipGT-
1905 Exocervical 
convex ,19mm 
1 1 185.00USD 1 185.00USD 
019002/1910 
MedGyn 
croyotherapy Tip 
GT1910 
Endo/Exocervical 
cervical small 
1 1 185.00USD 1 185.00USD 
Carrying case for 
Cryotherapy system 
1 1 55.00USD 1 55.00USD 
Cryopart Exhaust 
Filter 100-1419 
1 1 15.00 1 15.00USD 
Shipping costs 1 1 450.00USD 1 450USD 
Total   2280.00USD 
Nitrous oxide 
cylinder deposit 
1 Cylinder “F” 2 
atmospheres(2x273) 
500,000.00 6 3,000,000.00Ugs 
Gas price 1 Cylinder 800,000.00 (94.22/100X240)= 
226 each cylinder 
40pple= 5.6= 6 
cylinders 
4,800,000.00Ugs 
Transport costs 1 1 2,000,000.00 1 2,000,000.00 
Total      9,800,000.00 
LEEP machine 1 1 7,000,000.00 1 7,329,295 
The cost of Cryotherapy per woman will be Ugshs 9,800,000.00; the cost of Cryotherapy per woman is 
Ugshs 43,363.00 .The cost of LEEP has been excluded, Table: 9 ,USD = Ugshs 4000.0 
Table 10: Cost of salaries and/ or, allowances 2nurses 
Item  Freq. Unit Unit cost Units Total 
Nurses payments 12 1 800,000 2 19,200,000.00 
Cost of training  2 nurses 
Trainees per deim 5 1 100,000. 2 1,000,000. 
Trainees transport  5 1 5000. 2 50,000. 
Note book 1 1 2000. 2 4000. 
Training materials  1 1 100,000. 1 100,000. 
Training venue 1 1 100,000. 5 100,000. 
Projector  1 1 250,000. 5 750,000. 
Trainers fee 5 1 100,000. 2 1,000,000. 
Trainer per diem 5 1 100,000. 2 1,000,000. 
Total      4,004,000. 
Out reaches 2 nurses/5000people 
Per diem 5000pple/40per day=125days 1 100,000.00 2 25,000,000.00 
Fuel  125 l 4000.00 40 20,000,000.00 
Care hire 125 1 70,000.00 1 8,750,000.00 
Mobilization  125 1 100,000.00 1 12,500,000.00 
Total      66,250,000.00 
When using two  stationary clinic nurses the cost will be Ugshs 23,204,000.00 in salaries and training, 
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however if using outreach model the cost in allowances and training will be 85,450,000.00, Table 10. USD = 
Ughs 4000.00 
Table: 11, Cost of using volunteers 
Item  Freq. Unit Unit cost Units Total 
Cost of training  20 volunteers  
Trainees per deim 5 1 100,000. 20 2,000,000. 
Trainees transport  5 1 5000. 20 100,000. 
Note book 1 1 2000. 20 40,000. 
Training materials  1 1 100,000. 1 100,000. 
Training venue 1 1 100,000. 5 100,000. 
Projector  1 1 250,000. 5 750,000. 
Trainers fee 5 1 100,000. 2 1,000,000. 
Trainer per diem 5 1 100,000. 2 1,000,000. 
Total      5,090,000. 
Cost of out reaches (20 volunteers)/5000women 
Per diem (20x20)=400ppper 
day=12days 
1 100,000.00 20 24,000,000.00 
Fuel  12 l 4000.00 40 1,920,000.00 
Care hire 12 1 70,000.00 1 840,000.00 
Mobilization  12 1 100,000.00 1 1,200,000.00 
Total      27,960,000. 
When using a group of 20 volunteers for the outreach model the cost will be Ugshs 33,050,000.00 in 
allowances and training, Table: 11, USD = Ugshs 4000.00 
 
DISCUSSION  
We established that the screening started in April 2009 through aid of an American non government organization 
known as Program for Appropriate Technology in Health (PATH) which provided the initial funding for 
equipment and clinic set-up. The ministry of health of Uganda provided clinic space, personnel and consumables. 
For the Human resource existing staff that were already on the government pay roll were recruited, except for the 
first 2 years whereby an extra nurse was hired by the donor. The nurses were supported by one gynecologist who 
was already employed by the neighboring Mbarara University of Science and Technology (MUST). Using 
already existing staff helps in reducing costs of recruitment and payment of additional staff which may not have 
been budgeted for by the ministries concerned. This can be achieved by training in service staff in cervical 
cancer screening methods as was the case at MRRH. Clinic space was achieved by rehabilitation of already 
existing infrastructure. 
Mobilization of women was through locally available means such as local FM radios, televisions, 
churches and mosques, politicians and village health teams. This kind of mobilization helps in cutting costs of 
holding outreaches for mobilization and sensitization. 
 Out of 4659 women screened in 2013, 73.2% were below 50 years and therefore eligible for VIA, 
17.7% were 50 years and above and hence required Pap smear screening .This results shows that majority of 
women can be screened by DVI and therefore a few Pap smear will be needed in the program and hence reduce 
the costs and burden to the Laboratory. 
 The women came from the districts of southwestern Uganda and beyond, with majority (55.0%) 
coming from Mbarara district. Most of the women (71.3%) were from rural areas outside Mbarara Municipality. 
This shows that since women come from far hence screening methods that require multiple visits will necessitate 
“large” sums of money in transport which will discourage women from coming for screening.  
The prevalence of HIV was 19.0%. Though this is not the population figure, the prevalence is quite 
high and since literature has shown a strong association between HIV and cervical cancer, there is great need for 
finding a cost effective and sustainable screening policy at MRRH and other low resource setting where the 
burden of both HIV and human papilloama virus (HPV) the virus that causes cervical cancer are high. 
 Cervical intraepithelial neoplasia comprised (4.8%), 225cases, while cervical cancer comprised (2.7%) 
125cases. This means that whereas most patients had cin and can be treated by “see and treat” approach, there is 
a need for incorporating biopsies to address women with a diagnosis of suspicious for cancer.  
Most of the women, 94.2% were treated with Cryotherapy, 5.3% were treated by LEEP and one total 
abdominal hysterectomy. This means that majority of women will fit in a single visit approach and therefore 
reduce costs. When well trained Cryotherapy can safely be used by nurses and midwives, which can be done as 
outpatient procedure and also reduce on waiting time in absence of a doctor. However we recommend that LEEP 
services should be accessible either at the primary screening site or referral site to address women with large 
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lesions and those ineligible for Cryotherapy. 
The cost of reusable requirements for setting up a cervical cancer screening clinic was determined to be 
Ugshs 11,730,000.00. The cost of screening a population of 4659 at Mbarara Regional Referral Hospital in 2013 
was Ugshs 54, 302, 200.00, the cost of screening one woman using acetic acid was Ugshs 152.00, and Pap smear 
per woman is Ugshs 55,000.00 which is 361 times higher than DVI with acetic acid. While the cost of screening 
using lugol’s iodine will be Ugsh 4,000.00, which is 26 times higher than DVI with acetic acid.  The cost of cin 
treatment in a population of 3569 women is Ugshs 9,800,000.00 plus 2280.00USD. Cryotherapy per woman is 
Ugshs 46,226.00. (The cost of gloves, cotton, gauze and reusable  equipment such as speculums and Cryotherapy 
unit is not included is not included). This result shows that VIA and Cryotherapy is the most cost effective 
methods for screening and treatment of cin. 
The total cost of screening a population of 5000 will be 58, 351,000.00. The cost of acetic acid 
screening per woman is Ugshs 152.00 and Ugshs 55,000.00 (361times higher) with Pap smear, but Ugshs 
4,000.00 with lugol’s iodine. The cost of Cryotherapy in a population of 5000woman will be Ugshs 9,800,000.00; 
the cost of Cryotherapy per woman is Ugshs 43,363.00(the cost of gloves, cotton, gauze and reusable equipment  
such as speculums and Cryotherapy unit is not included). 
When using two stationary clinic nurses to screen a population of 5000 women the cost will be Ugshs 
23,204,000.00 in salaries and training, however if using outreach model the cost in allowances and training will 
be Ugshs 85,450,000.00.  When using a group of 20 volunteers for the outreach model the cost will be Ugshs 
33,050,000.00 in allowances and training. The most cost effective method in terms of money is a stationary 
clinic. However when you consider time outreaches by volunteers are the most cost effective because a 
stationary clinic will take 240 days, two clinic nurses in outreaches will take 125 days while volunteer 
outreaches will take 12 days to screen a population of 5000 women. .Below is some of the studies that evaluated 
the cost effectiveness of the different cervical cancer screening and treatment methods. 
Cervical cancer is an important public health problem among adult women in developing countries in 
South and Central America, sub-Saharan Africa, and south and south-east Asia. Frequently repeated cytology 
screening programs  either organiz ed or opportunistic  have led to a large decline in cervical cancer 
incidence and mortality in developed countries. In contrast, cervical cancer remains largely uncontrolled in high-
risk developing countries because of ineffective or no screening. This article briefly reviews the experience from 
existing screening and research initiatives in developing countries. 
Substantial costs are involved in providing the infrastructure, manpower, consumables, follow-up and 
surveillance for both organized and opportunistic screening programmes for cervical cancer. Owing to their 
limited health care resources, developing countries cannot afford the models of frequently repeated screening of 
women over a wide age range that is used in developed countries. Many low-income developing countries, 
including most in sub-Saharan Africa, have neither the resources nor the capacity for their health services to 
organize and sustain any kind of screening programme. Middle-income developing countries, which currently 
provide inefficient screening, should reorganize their programmes in the light of experiences from other 
countries and lessons from their past failures. Middle-income countries intending to organize a new screening 
programme should start first in a limited geographical area, before considering any expansion. It is also more 
realistic and effective to target the screening on high-risk women once or twice in their lifetime using a highly 
sensitive test, with an emphasis on high coverage (>80%) of the targeted population. 
Efforts to organize an effective screening programme in these developing countries will have to find 
adequate financial resources, develop the infrastructure, train the needed manpower, and elaborate surveillance 
mechanisms for screening, investigating, treating, and following up the targeted women. The findings from the 
large body of research on various screening approaches carried out in developing countries and from the 
available managerial guidelines should be taken into account when reorganizing existing programmes and when 
considering new screening initiatives.(Sankaranarayanan et al., 2001).  
A study was conducted whose objective was to evaluate the cost-effectiveness of human papillomavirus 
(HPV) DNA testing as a primary screening test in combination with cervical cytology in women aged 30 years 
or more. A state-transition mathematical model was used to simulate the natural history of HPV and cervical 
cancer in a cohort of U.S. women. Strategies included no screening and screening at different frequencies with 
conventional cytology, liquid-based cytology with HPV testing used for triage of equivocal results, and HPV 
DNA testing and cytology in combination after women had reached the age of 30. Outcomes measured included 
cancer incidence, life expectancy, lifetime costs, and incremental cost-effectiveness ratios. The results showed 
that the estimated reduction in lifetime risk of cervical cancer varies from 81% to 93% depending on the 
screening frequency, type of cytology, and test strategy. Every 3-year screening with liquid-based cytology 
administered to women at all ages and every 3-year screening using HPV DNA testing and cytology in 
combination administered to women aged 30 years or more provide equivalent or greater benefits than those 
provided by annual conventional cytology and have incremental cost-effectiveness ratios of $95,300 and 
$228,700 per year of life gained, respectively. In comparison, annual screening with HPV DNA testing and 
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cytology in combination provides only a few hours of additional life expectancy and has a cost-effectiveness 
ratio of more than $2,000,000 per year of life gained. In conclusion for women aged 30 years and more, every 2- 
or 3-year screening strategy that uses either HPV DNA testing in combination with cytology for primary 
screening or cytology with reflex HPV DNA testing for equivocal results will provide a greater reduction in 
cancer and be less costly than annual conventional cytology.(Goldie et al., 2004).   
Cervical cancer is the most common cancer among women in developing countries. Assessment was 
done to determine the effect of screening using visual inspection with 4% acetic acid (VIA) on cervical cancer 
incidence and mortality in a cluster randomised controlled trial in India. Of the 114 study clusters in Dindigul 
district, India, 57 were randomised to one round of VIA by trained nurses, and 57 to a control group. Healthy 
women aged 30 to 59 years were eligible for the study. Screen-positive women had colposcopy, directed 
biopsies, and, where appropriate, cryotherapy by nurses during the screening visit. Those with larger 
precancerous lesions or invasive cancers were referred for appropriate investigations and treatment. Cervical 
cancer incidence and mortality in the study groups were analysed and compared using Cox regression taking the 
cluster design into account, and analysis was by intention to treat. The primary outcome measures were cervical 
cancer incidence and mortality. Of the 49 311 eligible women in the intervention group, 31 343 (63·6%) were 
screened during 2000–03; 30 958 control women received the standard care. Of the 3088 (9·9%) screened 
positive, 3052 had colposcopy, and 2539 directed biopsy. Of the 1874 women with precancerous lesions in the 
intervention group, 72% received treatment. In the intervention group, 274 430 person years, 167 cervical cancer 
cases, and 83 cervical cancer deaths were accrued compared with 178 781 person-years, 158 cases, and 92 
deaths and in the control group during 2000–06 (incidence hazard ratio 0·75 [95% CI 0·55–0·95] and mortality 
hazard ratio 0·65 [0·47–0·89]). This shows that VIA screening, in the presence of good training and sustained 
quality assurance, is an effective method to prevent cervical cancer in developing countries.(Sankaranarayanan et 
al., 2007). 
Cervical cancer is a leading cause of cancer-related death among women in developing countries. In  
low-resource settings, cytology-based screening is difficult to implement, and less complex strategies may offer 
additional options. The objective was to assess the cost-effectiveness of several cervical cancer screening 
strategies using population-specific data. Cost-effectiveness was determined by analysis using a mathematical 
model and a hypothetical cohort of previously unscreened 30-year-old black South African women. Screening 
tests included direct visual inspection (DVI) of the cervix, cytologic methods, and testing for high-risk types of 
human papillomavirus (HPV) DNA. Strategies differed by number of clinical visits, screening frequency, and 
response to a positive test result. Data sources included a South African screening study, national surveys and fee 
schedules, and published literature. The main outcome measures years of life saved (YLS), lifetime costs in US 
dollars, and incremental cost-effectiveness ratios (cost per YLS). The results showed that when analyzing all 
strategies performed as a single lifetime screen at age 35 years compared with no screening, HPV testing 
followed by treatment of screen-positive women at a second visit, cost $39/YLS (27% cancer incidence 
reduction); DVI, coupled with immediate treatment of screen-positive women at the first visit was next most 
effective (26% cancer incidence reduction) and was cost saving; cytology, followed by treatment of screen-
positive women at a second visit was least effective (19% cancer incidence reduction) at a cost of $81/YLS. For 
any given screening frequency, when strategies were compared incrementally, HPV DNA testing generally was 
more effective but also more costly than DVI, and always was more effective and less costly than cytology. 
When comparing all strategies simultaneously across screening frequencies, DVI was the nondominated strategy 
up to a frequency of every 3 years (incremental cost-effectiveness ratio, $460/YLS), and HPV testing every 3 
years (incremental cost-effectiveness ratio, $11 500/YLS) was the most effective strategy. The conclusion was 
that cervical cancer screening strategies that incorporate DVI or HPV DNA testing and eliminate colposcopy 
may offer attractive alternatives to cytology-based screening programs in low-resource settings.(Goldie et al., 
2001).  
In another study was conducted who’s objective was to determine the potential effects on costs and 
outcomes of changes in sensitivity and specificity with new screening methods for cervical cancer. Using a 
Markov model of the natural history of cervical cancer, the effects of sensitivity, specificity, and screening 
frequency on cost-effectiveness were estimated. The estimates of conventional Papanicolaou test sensitivity of 
51% and specificity of 97% were obtained from a meta-analysis. The effect of reducing false-negative rates from 
40–90% and increasing false-positive rates by up to 20%, independently and jointly estimated. The marginal cost 
of improving sensitivity varied from $0 to $15. When specificity was held constant, increasing sensitivity of the 
Papanicolaou test increased life expectancy and costs. When sensitivity was held constant, decreasing specificity 
of the Papanicolaou test increased costs, an effect that was more dramatic at more frequent intervals. Decreased 
specificity had a substantial effect on cost-effectiveness estimates of improved Papanicolaou test sensitivity. 
Most of those effects are related to the cost of evaluation and treatment of low-grade lesions. It was concluded 
that policies or technologies that increased sensitivity of cervical cytologic screening increased overall costs, 
even if the cost of the technology was identical to that of conventional Papanicolaou smears. These effects 
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appear to be caused by relatively high prevalence of low-grade lesions and are magnified at frequent screening 
intervals. Efficient cervical cancer screening requires methods with greater ability to detect lesions that are most 
likely to become cancerous.(Myers et al., 2000). 
Another study was performed to determine the effect of noncytologic methods of screening for cervical 
carcinoma and its precursor lesions are needed for resource-poor settings in which cervical carcinoma continue 
to be an important cause of morbidity and mortality. Two thousand nine hundred forty-four women ages 35–65 
years were recruited from Cape Town, South Africa and screened using a combination of a Papanicolaou (Pap) 
smear, human papillomavirus (HPV) DNA testing, direct visual inspection after the application of a 5% acetic 
acid solution (DVI), and cervicography. Cervicography was considered primarily as a method with which to 
quality control the DVI examinations. Women with squamous intraepithelial lesions (SIL) or carcinoma on Pap 
smear, positive DVI examination (acetowhite lesion or cervical ulcer/growth), high levels of high risk HPV 
DNA (relative light units [RLU] > 10× positive control), or positive Cervigram™ were referred for colposcopy 
and cervical biopsy. Pap smears were positive in 8.1% of all women screened and identified 65 (78%) of all 
cases of biopsy confirmed high grade disease (high grade SIL or invasive carcinoma). DVI and cervicography 
were classified as positive in 18.1% and 10.5%, respectively, of women screened and identified 58 (67%) and 46 
(58%) of all cases of high grade disease, respectively. The results of HPV DNA testing varied depending on the 
cutoff value used to define a positive result. At the standard cutoff level (RLU > 1× positive control), 16.2% of 
women screened were classified as high risk HPV DNA positive, as were 63 women with high grade disease 
(73%). DVI and HPV DNA testing identified similar numbers of high grade SIL (cervical intraepithelial 
neoplasia Grade 2,3) and invasive carcinoma cases as Pap smears. However, both classify considerably more 
women without cervical disease as being test positive. Cancer 2000; 89:826–33. © 2000 American Cancer 
Society.(Denny et al., 2000) 
 
Conclusion 
Cytologic screening is several times more costly than direct visual inspection (DVI). Visual inspection screening 
of the cervical and treatment with Cryotherapy can be used as a cost effective alternative method to cytologic 
examination for control of cervical cancer in low resource areas. Using existing staff and integration of screening 
services into existing services into annual hospital budget helps in sustainability of donor initiated cervical 
cancer screening programs.  
 
Recommendations 
Cervical cancer screening programs in low resource areas should adopt direct visual inspection using 3-5% 
acetic acid as the main screening method and “see and treat” approach for treatment of positive lesions. For 
program sustainability cervical cancer screening services should be integrated into the main hospital programs 
and annual budget. Existing personnel and infrastructure should be used for cost effectiveness and sustainability. 
The primary screening clinic for a population of 5000 women should have 5liters of 100% acetic acid, a 
Cryotherapy unit, 5 medium cylinders of nitrous oxide gas, 2 nurses and enough consumables per year for 
effective running and sustainability.  In addition to the above there should be an accessible referral clinic/hospital 
which can do Pap smears, colposcopy, biopsy, LEEP, hysterectomy and radiotherapy. 
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